Pubblicazioni

Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results

2019 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Deangelo, Daniel J.; Mauro, Michael J.; Kim, Dong-Wook; Cortes, Jorge; RÃ©a, Delphine; Hughes, Timothy P.; Minami, Hironobu; Breccia, Massimo; Talpaz, Moshe; Hochhaus, Andreas; Tee Goh, Yeow; Le Coutre, Philipp D.; Sondhi, Manu; Mishra, Kaushal; Hourcade-Potelleret, Florence; Vanasse, Gary; Aimone, Paola; Lang, Fabian

Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation

2019 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Deininger, Michael W.; RÃ©a, Delphine; Lang, Fabian; Kim, Dong-Wook; Cortes, Jorge E.; Hughes, Timothy P.; Minami, Hironobu; Breccia, Massimo; Deangelo, Daniel J.; Hochhaus, Andreas; Talpaz, Moshe; Tee Goh, Yeow; Le Coutre, Philipp D.; Etienne, Gabriel; Sondhi, Manu; Mishra, Kaushal; Aimone, Paola; Mauro, Michael J.